Recombinant Human DLL4 Protein(His Tag)

SKU: PDMH100443

Size:100μg

Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping:This product is provided as lyophilized powder which is shipped with ice packs.

Exp date:12 months

Category ID_II:Recombinant Proteins

Category ID_III:Others

Abbreviation:DLL4

Target Synonym:DLL;AOS;UNQ;PRO;Delta-like protein;Drosophila Delta homolog;Delta;hdelta;DLL4;AOS6;hdelta2;Delta4;Delta-like protein 4;Drosophila Delta homolog 4;UNQ1895;PRO4341;Delta 4;delta 4 precursor;Delta ligand 4;delta ligand 4 precursor;Delta like 4;Delta like 4 homolog;Delta like 4 protein;Delta like canonical Notch ligand 4;Delta like protein 4;Delta-like 4 (Drosophila);DLL 4;Homeobox protein DLL-4;MGC126344;Notch ligand delta 2;Notch ligand DLL4;Notch ligand DLL4 precursor;XDLL-4

Research Areas:Developmental Biology;Signal Transduction;Cancer

Conjugation:

Target Species:Human

Expression Host:Mammalian

Application:

Fusion tag:C-His

UNIProt ID:Q9NR61

Accession:Q9NR61

Background:Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

Concentration:

Activity:Not validated for activity

Sequence:Ser27-Pro524

Purity:> 90% as determined by reducing SDS-PAGE.

Formulation:Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis

Endotoxin:< 1.0 EU/mg of the protein as determined by the LAL method

Calculated MW:54.7 kDa

ObservedMW:60-65 kDa